Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Bill Williams says BriaCell further modified its OTS cells to express co-stimulatory molecules and cytokines. In lab studies, these OTS Plus cells activated naive T cells and killed cancer cells on repeated challenges, suggesting stronger and more durable immune activation than just HLA matching alone.

Related Insights

Evolveimmune's key scientific differentiator is delivering two critical T-cell activation signals (the conventional signal and a CD2 co-stimulation signal) within a single molecule. This is a deliberate strategic choice against competitors who may use two separate molecules, based on the belief that a single, integrated agent provides a superior, optimized T-cell response.

Most cell therapies target a single antigen on cancer cells. Luminary engineers its cells to recognize three different receptors. The therapy only needs one of the three to be present to work, making it significantly harder for cancer cells to mutate and "escape" the treatment.

For heavily pretreated melanoma patients, standard T-cell growth methods were failing. By adding a 4-1BB agonistic co-stimulation during expansion, the team dramatically increased their ability to grow enough cells for therapy. This single process change increased manufacturing success from 50% to 95% for this difficult patient population.

Dr. Patrick Baeuerle suggests that instead of engineering complex co-stimulatory signals into T-cell engagers, a more effective strategy is to combine them with standard-of-care treatments like chemotherapy or ADCs. This approach dramatically augments efficacy and has already prompted multiple Phase 3 trials.

Bill Williams says HLA matching was not as critical for Bria-IMT when combined with an immune checkpoint inhibitor, so BriaCell is not matching patients for that product. The company is instead building HLA matching into its next-generation Bria-OTS and OTS Plus pipelines as those programs advance.

Create's strategy is not limited to a single cell type. They view success in solid tumors as requiring the programming of all immune cells. Their platform can specifically engineer myeloid cells, T-cells, and NK cells in vivo, orchestrating a coordinated, multi-pronged attack on cancer.

Bill Williams says BriaCell's engineered OTS cell lines express 15 HLA molecules across four lines. That lets them single-match over 99% of the population and double-match over 90%, making a personalized off-the-shelf therapy practical after only a one-week saliva test rather than complex tumor sequencing.

Bill Williams says Bria-IMT presents many cancer-associated antigens, not just one, so it can activate adaptive T cells against multiple mutated tumor clones. He adds the cell-based approach also engages the innate immune system, which can recognize tumors undergoing immune evasion, further limiting cancer's ability to escape.

Unlike CAR-T therapies that rely on a limited number of engineered cells, T-cell engagers activate the body's entire T-cell repertoire. This vast pool of effector cells makes exhaustion a negligible issue, as only a small fraction is engaged at any time, ensuring a sustained attack on cancer cells.

To combat immunosuppressive "cold" tumors, new trispecific antibodies are emerging. Unlike standard T-cell engagers that only provide the primary CD3 activation signal, these drugs also deliver the crucial co-stimulatory signal (e.g., via CD28), ensuring full T-cell activation in microenvironments where this second signal is naturally absent.